Should I buy or sell Avid Bioservices stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CDMO shares. View CDMO analyst ratings or view top-rated stocks .

What is Avid Bioservices' stock price target for 2024?

4 equities research analysts have issued 12 month price objectives for Avid Bioservices' shares. Their CDMO share price targets range from $7.00 to $20.00. On average, they predict the company's share price to reach $14.25 in the next year. This suggests a possible upside of 123.0% from the stock's current price. View analysts price targets for CDMO or view top-rated stocks among Wall Street analysts .

How have CDMO shares performed in 2024?

Avid Bioservices' stock was trading at $6.50 on January 1st, 2024. Since then, CDMO stock has decreased by 1.7% and is now trading at $6.39. View the best growth stocks for 2024 here .

Are investors shorting Avid Bioservices?

Avid Bioservices saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 10,110,000 shares, a drop of 6.7% from the March 15th total of 10,840,000 shares. Based on an average daily trading volume, of 1,330,000 shares, the short-interest ratio is presently 7.6 days. View Avid Bioservices' Short Interest .

When is Avid Bioservices' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 22nd 2024. View our CDMO earnings forecast .

How were Avid Bioservices' earnings last quarter?

Avid Bioservices, Inc. (NASDAQ:CDMO) posted its quarterly earnings data on Wednesday, June, 21st. The biopharmaceutical company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.07. The biopharmaceutical company had revenue of $39.80 million for the quarter, compared to the consensus estimate of $39 million. Avid Bioservices had a negative trailing twelve-month return on equity of 5.18% and a negative net margin of 8.12%. During the same quarter in the previous year, the firm posted $0.04 EPS.

What ETF holds Avid Bioservices' stock?

Franklin Genomic Advancements ETF holds 12,366 shares of CDMO stock, representing 1.47% of its portfolio.

When did Avid Bioservices' stock split?

Shares of Avid Bioservices reverse split before market open on Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 7th 2017. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

What guidance has Avid Bioservices issued on next quarter's earnings?

Avid Bioservices updated its third quarter 2024 earnings guidance on Wednesday, March, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $33.8 million-$33.8 million, compared to the consensus revenue estimate of $34.2 million.

What is Roger Lias' approval rating as Avid Bioservices' CEO?

5 employees have rated Avid Bioservices Chief Executive Officer Roger Lias on Glassdoor.com . Roger Lias has an approval rating of 49% among the company's employees. This puts Roger Lias in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 63.0% of employees surveyed would recommend working at Avid Bioservices to a friend.

What other stocks do shareholders of Avid Bioservices own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avid Bioservices investors own include Array Technologies (ARRY) , Anavex Life Sciences (AVXL) , Inovio Pharmaceuticals (INO) , Advanced Micro Devices (AMD) , Dynavax Technologies (DVAX) , Micron Technology (MU) , QUALCOMM (QCOM) , NVIDIA (NVDA) , Novavax (NVAX) and Pfizer (PFE) .

Who are Avid Bioservices' major shareholders?

Avid Bioservices' stock is owned by many different retail and institutional investors. Top institutional shareholders include Mather Group LLC. (0.01%) and CWM LLC (0.01%). Insiders that own company stock include Daniel R Hart , Gregory Sargen, Joseph Carleone, Mark R Ziebell , Matthew R Kwietniak, Nicholas Stewart Green , Richard A Richieri and Richard B Hancock . View institutional ownership trends .

How do I buy shares of Avid Bioservices?

Shares of CDMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CDMO

Avid Bioservices (CDMO) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free CDMO Stock Alerts

$6.39

-0.13 (-1.99%)

(As of 04/19/2024 ET)

Compare

Today's Range: $6.23
▼
$6.59
50-Day Range: $6.09
▼
$8.79
52-Week Range: $4.07
▼
$19.97

Volume: 793,712 shs
Average Volume: 1.28 million shs
Market Capitalization: $404.10 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $14.25

Get Avid Bioservices alerts:

Avid Bioservices MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 123.0% Upside
$14.25 Price Target
Short Interest: Healthy
15.99% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.96
Upright™ Environmental Score
News Sentiment: 1.04
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.85 out of 5 stars

Medical Sector

202nd out of 911 stocks

Pharmaceutical Preparations Industry

77th out of 411 stocks

3.4

Analyst's Opinion

Consensus Rating
Avid Bioservices has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Avid Bioservices has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
15.99% of the outstanding shares of Avid Bioservices have been sold short.
Short Interest Ratio / Days to Cover
Avid Bioservices has a short interest ratio ("days to cover") of 7.6.
Change versus previous month
Short interest in Avid Bioservices has recently decreased by 6.73%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Avid Bioservices does not currently pay a dividend.
Dividend Growth
Avid Bioservices does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Avid Bioservices has received a 68.99% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Biopharmaceuticals", "Clinical research services", and "Process engineering services for the pharmaceutical industry" products. See details.
Environmental Sustainability
The Environmental Impact score for Avid Bioservices is -0.96.

2.8

News and Social Media Coverage

News Sentiment
Avid Bioservices has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Avid Bioservices this week, compared to 1 article on an average week.
Search Interest
Only 3 people have searched for CDMO on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Avid Bioservices to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Avid Bioservices insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.39% of the stock of Avid Bioservices is held by insiders.
Percentage Held by Institutions
97.16% of the stock of Avid Bioservices is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Avid Bioservices is -37.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Avid Bioservices is -37.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Avid Bioservices has a P/B Ratio of 2.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

About Avid Bioservices Stock (NASDAQ:CDMO)

Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services of biologics for the biotechnology and biopharmaceutical industries. The company offers various services, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.

CDMO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CDMO Stock News Headlines

April 18, 2024 | americanbankingnews.com

Avid Bioservices, Inc. (NASDAQ:CDMO) Short Interest Update

April 12, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMO

April 20, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

April 4, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMO

March 27, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMO

March 20, 2024 | globenewswire.com

Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q

March 20, 2024 | finance.yahoo.com

CDMO Dec 2024 10.000 call

March 16, 2024 | ca.finance.yahoo.com

CDMO Apr 2024 15.000 call

April 20, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

March 16, 2024 | ca.finance.yahoo.com

CDMO Dec 2024 2.500 call

March 14, 2024 | businesswire.com

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Avid Bioservices, Inc. (CDMO) on Behalf of Investors

March 14, 2024 | businesswire.com

Avid Bioservices, Inc. (CDMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

March 13, 2024 | businesswire.com

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Avid Bioservices, Inc. (CDMO) on Behalf of Investors

March 13, 2024 | businesswire.com

The Law Offices of Frank R. Cruz Announces Investigation of Avid Bioservices, Inc. (CDMO) on Behalf of Investors

March 7, 2024 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Alimera (ALIM), Avid Bioservices (CDMO)

March 7, 2024 | investorplace.com

Why Is Avid Bioservices (CDMO) Stock Down 30% Today?

March 7, 2024 | marketwatch.com

Avid Bioservices Shares Slide After Pricing Private Placement of Convertible Notes